Alcon AG is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Alcon AG in the market are Johnson & Johnson Vision, Bausch Health Companies Inc., and Novartis AG.

Alcon AG is a renowned company with a rich history and background. Established in XYZ, Alcon AG has become a leading player in the industry. The company specializes in XYZ products and services, catering to a wide range of customers worldwide. Over the years, Alcon AG has achieved significant milestones and global recognition for its innovative solutions and exceptional quality. With a strong commitment to excellence, Alcon AG continues to expand its presence and investment in research and development. With a solid track record, Alcon AG has remained a trusted choice for investors seeking growth and reliability in the market.

Alcon AG, a renowned stock, has achieved significant milestones throughout its journey. The company has successfully introduced groundbreaking products and technologies in the field of eye care. Alcon AG's major achievements include the development of revolutionary intraocular lenses (IOLs) that have enhanced vision correction and improved patients' quality of life. Additionally, the company pioneered innovative surgical equipment and techniques, such as advanced phacoemulsification devices, revolutionizing cataract surgery. Alcon AG has dedicated itself to providing cutting-edge ophthalmic solutions, elevating the standards of eye care globally. With its impressive track record, Alcon AG stands out as a leading entity within the stock market.

Alcon AG primarily operates in various countries and regions worldwide. With its global presence, the company has established a strong foothold in key markets across the Americas, Europe, Asia, and Africa. Alcon AG's extensive reach includes countries such as the United States, Germany, Switzerland, France, China, Japan, Australia, South Africa, and many others. The company's strategic expansion allows it to cater to a diverse clientele, providing innovative eye care products and services internationally.

Alcon AG represents a strong commitment to values and a clear corporate philosophy. The company prioritizes integrity, innovation, and excellence in all aspects of its operations. Alcon is dedicated to improving vision care and providing high-quality eye care products and services to its customers. With a focus on continuous research and development, Alcon aims to deliver cutting-edge solutions for eye health. By upholding these values and embracing a forward-thinking approach, Alcon AG sets itself apart as a trusted and leading player in the field of ophthalmic innovation.

Analysts currently set an average price target of 104.65 USD for the Alcon stock (median: 104.14 USD), implying +57.8 % versus the latest price. The consensus is based on 20 analyst ratings.

Alcon Analyst Price Targets 2026

20 analysts currently rate the Alcon stock: 16 recommend buying, 2 holding and 2 selling. For 2026, analysts expect Alcon to generate revenue of 10.99 B USD and earnings per share of 3.46 USD.

Alcon Analyst Price Targets 2026

Converted at the current exchange rate, the Alcon share trades at 62.81 EUR (73.37 USD).

The Alcon share (ALC.SW) is listed on 7 stock exchanges, including: NYSE (ALC), Frankfurt (2U3.F), München (2U3.MU), Düsseldorf (2U3.DU), Hamburg (2U3.HM), London (0A0D.L), SIX (Zürich) (ALC.SW).

Alcon AG is a global company that offers a wide range of eye care products for patients and medical professionals. The company specializes in developing and manufacturing innovative solutions for optimal vision and eye health. Alcon operates in over 75 countries worldwide. Alcon has five main business areas: Surgery, Vision Care, Pharma, Ophthalmic Devices, and Ophthalmic Instruments. The Surgery division specializes in surgical procedures such as cataract surgery and retinal surgery. The Vision Care division deals with contact lenses, glasses, and other vision correction products. The Pharma division includes medications for treating eye diseases such as glaucoma and allergic conjunctivitis. The Ophthalmic Devices and Ophthalmic Instruments divisions specialize in medical accessories and instruments. Alcon's most well-known product is the Air Optix contact lens, available in various designs and materials, which allows for longer wear time. The Dailies contact lens line and the TrueTear therapy for dry eyes are also popular Alcon products. Alcon has also developed some innovative technologies, including the ORA System, which allows for more precise measurements of eye data during cataract surgery, and the WaveLight Refractive Suite for correcting refractive errors such as myopia, hyperopia, and astigmatism. Another important product from Alcon is Restasis, a medication for treating dry eyes. It is the first FDA-approved medication to stimulate natural tear production. Alcon's business model is based on innovation and quality. The company heavily invests in research and development to develop the eye care solutions of the future. Alcon also has a strong presence in the education and training of eye doctors and other medical professionals. The company offers training and continuing education to keep doctors and professionals up to date and help them utilize Alcon's innovative technologies and products. Alcon also has a strong online presence and offers a wide range of digital resources, including online training, resources for medical professionals and patients, and videos on eye care products and technologies. Overall, Alcon is a leading company in the eye care industry that focuses on innovation and quality. With a wide range of products and services and a strong presence in medical education and training, Alcon is well positioned to continue growing and improving eye health and vision worldwide.

The expected revenue of Alcon is 10.99 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Alcon is 1.70 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Alcon is currently 21.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alcon stock.

The price-to-sales ratio (P/S) of Alcon is currently 3.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alcon stock.

The Eulerpool Quality Score for Alcon is 5/10.

The ISIN of Alcon is CH0432492467. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Alcon is A2PDXE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Alcon is ALC.SW. The ticker symbol is used to trade Alcon shares on the stock exchange.

Over the past 12 months, Alcon paid a dividend of 0.28 USD . This corresponds to a dividend yield of about 0.38 %. For the coming 12 months, Alcon is expected to pay a dividend of 0.34 USD.

The current dividend yield of Alcon is 0.38 %.

Alcon pays a dividend, distributed in the months of , , , .

Alcon paid dividends every year for the past 5 years.

For the upcoming 12 months, dividends amounting to 0.34 USD are expected. This corresponds to a dividend yield of 0.51 %.

Alcon is assigned to the 'Health' sector.

In the year 2025, Alcon distributed 0.48 USD as dividends.

The dividends of Alcon are distributed in USD.